Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

APREA THERAPEUTICS, INC.

(APRE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Aprea Therapeutics, Inc.(NasdaqGS:APRE) dropped from S&P Global BMI Index

09/20/2021 | 12:00am EDT

Aprea Therapeutics, Inc.(NasdaqGS:APRE) dropped from S&P Global BMI Index


© S&P Capital IQ 2021
All news about APREA THERAPEUTICS, INC.
10/15APREA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
10/15Aprea Therapeutics, Inc. Announces Resignation of Johan Christenson from the Board of D..
CI
10/05INSIDER SELL : Aprea Therapeutics
MT
09/22INSIDER SELL : Aprea Therapeutics
MT
09/20APREA THERAPEUTICS : Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advan..
AQ
09/20Aprea Therapeutics, Inc. Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) i..
CI
09/20Top Premarket Gainers
MT
09/20APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from S&P Global BMI Index
CI
09/14APREA THERAPEUTICS : to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Soli..
AQ
09/14Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Sol..
CI
More news
Analyst Recommendations on APREA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -37,3 M - -
Net cash 2021 56,2 M - -
P/E ratio 2021 -2,71x
Yield 2021 -
Capitalization 101 M 101 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 11
Free-Float 89,9%
Chart APREA THERAPEUTICS, INC.
Duration : Period :
Aprea Therapeutics, Inc. Technical Analysis Chart | APRE | US03836J1025 | MarketScreener
Technical analysis trends APREA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 5
Last Close Price 4,75 $
Average target price 4,00 $
Spread / Average Target -15,8%
EPS Revisions
Managers and Directors
Christian S. Schade Chairman, President & Chief Executive Officer
Scott M. Coiante Chief Financial Officer, Secretary & Senior VP
Eyal C. Attar Chief Medical Officer & Senior Vice President
Lars Abrahmsén Chief Scientific Officer & Senior Vice President
Johan Rutger Christenson Independent Director
Sector and Competitors
1st jan.Capi. (M$)
APREA THERAPEUTICS, INC.-3.46%101
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455